NuVasive (NUVA) Tops Q4 EPS by 2c

Go back to NuVasive (NUVA) Tops Q4 EPS by 2c

NuVasive (NUVA) PT Raised to $82 at UBS

February 10, 2017 9:19 AM EST

UBS analyst Matt Miksic reiterates Buy rating and raises price target on NuVasive Inc. (NASDAQ: NUVA) to $82 (from $71), as the companys sales surpass pre-announcement, driven by a one-time order, while management makes progress on margins.

Miksic comments, "Management delivered upside to the company's... More

NuVasive (NUVA) PT Raised to $80 at Barclays

February 10, 2017 8:46 AM EST

Barclays raised its price target on NuVasive (NASDAQ: NUVA) to $80.00 (from $76.00) while maintaining a Overweight rating.

... More

NuVasive (NUVA) PT Raised to $84 at Jefferies Following Results

February 10, 2017 8:05 AM EST

Jefferies analyst Raj Denhoy reiterates Buy rating and raises price target on NuVasive Inc. (NASDAQ: NUVA) to $84 (from $79), as the company delivered unexpected upside with fourth quarter revenues above consensus, yet provided guidance that appears conservative.

Denhoy comments, "NUVA progresses down a... More

NuVasive (NUVA) Hold Rating Maintained at Needham & Company Despite Growth Rebound

February 10, 2017 6:48 AM EST

Needham & Company analyst Mike Matson reiterates Hold rating on NuVasive Inc. (NASDAQ: NUVA), suggesting growth recovered in the fourth quarter of 2016 and now sees multiple levels for growth and margins in 2017.

Matson writes, "NUVA's 4Q16 revenue beat its 1/9/17 preannouncement and EPS beat consensus. And... More